US04963C2098
© BusinessWire
11.12.2025
ATRC
LISTED
NASDAQ
AtriCure Announces the First Patients Treated with Novel Dual Energy Platform
News Preview
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced successful first-in-human treatments using its novel dual energy platform that integrates Pulsed Field Ablation (PFA) with Advanced Radiof...
Themefolio
Profiler
Peergroup
© BusinessWire
18.11.2025
ATRC
LISTED
NASDAQ
AtriCure to Participate in the Piper Sandler 37th Annual Healthcare Conference
News Preview
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Piper Sandler 37th Annual Healthcare Conference.
AtriCure’s management is schedu...
Themefolio
Profiler
Peergroup
© BusinessWire
29.10.2025
ATRC
LISTED
NASDAQ
AtriCure Reports Third Quarter 2025 Financial Results; Raises Financial Outlook for 2025
News Preview
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced third quarter 2025 financial results.
“Our third quarter results demonstrate strong execution and patient focus across the business. We...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© BusinessWire
28.10.2025
ATRC
LISTED
NASDAQ
AtriCure Announces the First Patient Treated in the BoxX-NoAF Clinical Trial
News Preview
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced that the first patient was enrolled and treated in the Box Lesion Creation with Left Atrial Appendage Exclusion to Reduce the Occurrence o...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
27.10.2025
ATRC
LISTED
NASDAQ
AtriCure to Participate in Upcoming Investor Conferences
News Preview
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in upcoming investor conferences.
AtriCure’s management is scheduled to participate in a firesid...
Themefolio
Profiler
Peergroup
© BusinessWire
08.10.2025
ATRC
LISTED
NASDAQ
AtriCure to Announce Third Quarter 2025 Financial Results
News Preview
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its third quarter 2025 financial results on Wednesday, October 29, 2025.
AtriCure will host an audio webcast at 4:...
Themefolio
Profiler
Peergroup
© BusinessWire
09.09.2025
ATRC
LISTED
NASDAQ
AtriCure Announces the Launch of the cryoXT™ Device for Post-Operative Pain Management Following Amputation
News Preview
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced the launch of the cryoXT™ device, an innovative cryoablation technology used to help manage post-operative pain following amputation proce...
Themefolio
Profiler
Peergroup
© BusinessWire
20.08.2025
ATRC
LISTED
NASDAQ
AtriCure to Participate in the 2025 Wells Fargo Healthcare Conference
News Preview
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 2025 Wells Fargo Healthcare Conference.
AtriCure’s management is scheduled to pa...
Themefolio
Profiler
Peergroup
© BusinessWire
29.07.2025
ATRC
LISTED
NASDAQ
AtriCure Reports Second Quarter 2025 Financial Results; Raises Financial Outlook for 2025
News Preview
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced second quarter 2025 financial results.
“Our stellar results reflect the power of innovation and the growing impact of our expanding port...
Themefolio
Profiler
Peergroup
© BusinessWire
28.07.2025
ATRC
LISTED
NASDAQ
AtriCure to Participate in the Canaccord Genuity 45th Annual Growth Conference
News Preview
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Canaccord Genuity 45th Annual Growth Conference.
AtriCure’s management is schedu...
Themefolio
Profiler
Peergroup
© BusinessWire
15.07.2025
ATRC
LISTED
NASDAQ
AtriCure Completes Enrollment in LeAAPS Clinical Trial for Stroke Prevention
News Preview
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced the completion of enrollment in the left atrial appendage exclusion for prophylactic stroke reduction (LeAAPS) clinical trial (NCT05478304). Initiated...
Themefolio
Profiler
Peergroup
© BusinessWire
08.07.2025
ATRC
LISTED
NASDAQ
AtriCure to Announce Second Quarter 2025 Financial Results
News Preview
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its second quarter 2025 financial results on Tuesday, July 29, 2025.
AtriCure will host an audio webcast at 4:30 p...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
23.05.2025
ATRC
LISTED
NASDAQ
AtriCure to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
News Preview
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Goldman Sachs 46th Annual Global Healthcare Conference.
AtriCure’s management is...
Themefolio
Profiler
Peergroup
© BusinessWire
29.04.2025
ATRC
LISTED
NASDAQ
AtriCure Reports First Quarter 2025 Financial Results
News Preview
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced first quarter 2025 financial results.
“Our performance in the first quarter reflects outstanding execution of several new product launche...
Themefolio
Profiler
Peergroup
© BusinessWire
10.04.2025
ATRC
LISTED
NASDAQ
AtriCure Announces First Use of the AtriClip PRO-Mini® Device
News Preview
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced the first use of the newest AtriClip ® device for minimally invasive concomitant procedures, the AtriClip PRO-Mini® LAA Exclusion System....
Themefolio
Profiler
Peergroup
© BusinessWire
08.04.2025
ATRC
LISTED
NASDAQ
AtriCure to Announce First Quarter 2025 Financial Results
News Preview
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its first quarter 2025 financial results on Tuesday, April 29, 2025.
AtriCure will host an audio webcast at 4:30 p....
Themefolio
Profiler
Peergroup
© BusinessWire
12.03.2025
ATRC
LISTED
NASDAQ
AtriCure to Host Analyst & Investor Day on March 26, 2025
News Preview
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today reaffirmed that the company will host an Analyst & Investor Day at its headquarters in Mason, Ohio on Wednesday, March 26, 2025 from 1:00 pm to...
Themefolio
Profiler
Peergroup
© BusinessWire
12.02.2025
ATRC
LISTED
NASDAQ
AtriCure Reports Fourth Quarter 2024 and Full Year 2024 Financial Results
News Preview
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced fourth quarter 2024 and full year 2024 financial results.
“2024 was another outstanding year at AtriCure, marked by continued progress o...
Themefolio
Profiler
Peergroup
© BusinessWire
22.01.2025
ATRC
LISTED
NASDAQ
AtriCure to Announce Fourth Quarter and Full Year 2024 Financial Results
News Preview
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth quarter and full year 2024 financial results on Wednesday, February 12, 2025.
AtriCure will host an aud...
Themefolio
Profiler
Peergroup
© BusinessWire
13.01.2025
ATRC
LISTED
NASDAQ
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2024, Provides Financial Outlook for 2025, and Announces Upcoming Analyst & Investor Day
News Preview
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced preliminary financial results for the fourth quarter and full year 2024 and provided 2025 financial guidance. Additionally, AtriCure annou...
Themefolio
Profiler
Peergroup
© BusinessWire
23.12.2024
ATRC
LISTED
NASDAQ
AtriCure to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
News Preview
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 43rd Annual J.P. Morgan Healthcare Conference.
AtriCure’s management is schedule...
Themefolio
Profiler
Peergroup
© BusinessWire
20.11.2024
ATRC
LISTED
NASDAQ
AtriCure to Participate in the Piper Sandler 36th Annual Healthcare Conference
News Preview
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Piper Sandler 36th Annual Healthcare Conference.
AtriCure’s management is schedu...
Themefolio
Profiler
Peergroup
© BusinessWire
07.11.2024
ATRC
LISTED
NASDAQ
AtriCure to Participate in the Stifel 2024 Healthcare Conference
News Preview
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Stifel 2024 Healthcare Conference.
AtriCure’s management is scheduled to particip...
Themefolio
Profiler
Peergroup
© BusinessWire
29.10.2024
ATRC
LISTED
NASDAQ
AtriCure Reports Third Quarter 2024 Financial Results
News Preview
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced third quarter 2024 financial results.
“Our broad-based growth in the third quarter reflects strong, ongoing adoption trends throughout ou...
Themefolio
Profiler
Peergroup
© BusinessWire
28.10.2024
ATRC
LISTED
NASDAQ
AtriCure to Participate in the UBS Global Healthcare Conference
News Preview
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming UBS Global Healthcare Conference.
AtriCure’s management is scheduled to participa...
Themefolio
Profiler
Peergroup
© BusinessWire
15.10.2024
ATRC
LISTED
NASDAQ
AtriCure Announces Launch of cryoSPHERE MAX™ Probe for Post-Operative Pain Management
News Preview
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has launched the cryoSPHERE MAX™ cryoablation probe. The cryoSPHERE MAX probe features a larger ball tip designed to optimize Cry...
Themefolio
Profiler
Peergroup
© BusinessWire
08.10.2024
ATRC
LISTED
NASDAQ
AtriCure to Announce Third Quarter 2024 Financial Results
News Preview
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its third quarter 2024 financial results on Tuesday, October 29, 2024.
AtriCure will host an audio webcast at 4:30...
Themefolio
Profiler
Peergroup
© BusinessWire
01.10.2024
ATRC
LISTED
NASDAQ
AtriCure Receives CE-Mark for the EnCompass® Clamp
News Preview
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has received regulatory approval to sell the EnCompass® Clamp in CE-marked countries in the European Union, and European surgeons...
Themefolio
Profiler
Peergroup
© BusinessWire
27.08.2024
ATRC
LISTED
NASDAQ
AtriCure Announces that the First Patient has been Treated with the Revolutionary AtriClip® FLEX-Mini™ Device
News Preview
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the first patient was treated with the AtriClip® FLEX-Mini™ device, which recently received 510(k) clearance. The AtriClip FLEX-Mini...
Themefolio
Profiler
Peergroup
© BusinessWire
22.08.2024
ATRC
LISTED
NASDAQ
AtriCure Receives Expanded CE-Mark Indication for AtriClip® Devices for the Reduction of Stroke in Patients with Atrial Fibrillation
News Preview
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has received an expanded indication for the AtriClip® in CE-marked countries in Europe. The product is now indicated for use in p...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
